The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9,553 patients

References

• O’GaraPTKushnerFGAscheimDD2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesCirculation20131274e362e42523247304
   PubMed Web of Science ®Google Scholar
• GroveELWurtzMThomasMRKristensenSDAntiplatelet therapy in acute coronary syndromesExpert Opin Pharmacother201516142133214726293612
   PubMed Web of Science ®Google Scholar
• CowleyMJKuritzkyLDevelopments in antiplatelet therapy for acute coronary syndromes and considerations for long-term managementCurr Med Res Opin20092561477149019419337
   PubMed Web of Science ®Google Scholar
• IakovouISchmidtTBonizzoniEIncidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stentsJAMA2005293172126213015870416
   PubMed Web of Science ®Google Scholar
• DaemenJWenaweserPTsuchidaKEarly and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort studyLancet2007369956266767817321312
   PubMed Web of Science ®Google Scholar
• ParodiGMarcucciRValentiRHigh residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCIJAMA2011306111215122321934054
   PubMed Web of Science ®Google Scholar
• ConeJWangSTandonNComparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cellsJ Cardiovasc Pharmacol199934449750410511123
   PubMed Web of Science ®Google Scholar
• GotoSCilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleedingAtheroscler Suppl200564311
   PubMed Web of Science ®Google Scholar
• LeeKHAhnYKimSSKAMIR (Korea Acute Myocardial Infarction Registry) InvestigatorsComparison of triple anti-platelet therapy and dual anti-platelet therapy in patients with acute myocardial infarction who had no-reflow phenomenon during percutaneous coronary interventionCirc J201377122973298123986083
   PubMed Web of Science ®Google Scholar
• ChenKYRhaSWLiYJKorea Acute Myocardial Infarction Registry InvestigatorsTriple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionCirculation2009119253207321419528339
   PubMed Web of Science ®Google Scholar
• ChenYZhangYTangYHuangXXieYLong-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisonsCurr Med Res Opin2014301374924083626
   PubMed Web of Science ®Google Scholar
• SakuraiRKooBKKanedaHBonneauHNNagaiRCilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trialsInt J Cardiol201316752250225822727963
   PubMed Web of Science ®Google Scholar
• BundhunPKQinTChenMHComparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trialsBMC Cardiovasc Disord20151511826450578
   PubMed Web of Science ®Google Scholar
• LeeSWParkSWKimYHDrug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients)J Am Coll Cardiol200851121181118718355656
   PubMed Web of Science ®Google Scholar
• HaSJKimSJHwangSJEffect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary interventionCoron Artery Dis201324869069724152567
   PubMed Web of Science ®Google Scholar
• LeeSWParkSWKimYHDECLARE-LONG II Study InvestigatorsA randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions) trialJ Am Coll Cardiol201157111264127021392640
   PubMed Web of Science ®Google Scholar
• SongPSSongYBYangJHTriple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II RegistryHeart Vessels201530445846824682436
   PubMed Web of Science ®Google Scholar
• LeeHJYuCWHwangHKLong-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery diseaseCoron Artery Dis201324754254823994880
   PubMed Web of Science ®Google Scholar
• Biondi-ZoccaiGGAbbateAAgostoniPLong-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregressionAm Heart J2005149350451115864240
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• LaskeyWKYancyCWMaiselWHThrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7–8, 2006Circulation2007115172352235717470710
   PubMed Web of Science ®Google Scholar
• LiberatiAAltmanDGTetzlaffJThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaborationBMJ2009339b270019622552
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• LeeSWParkSWKimYHComparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial)Am J Cardiol200710071103110817884371
   PubMed Web of Science ®Google Scholar
• KimJYLeeKShinMCilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary interventionCirc J200771121867187218037738
   PubMed Web of Science ®Google Scholar
• JeongYHHwangJYKimISAdding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) studyCirc Cardiovasc Interv201031172620118150
   PubMed Web of Science ®Google Scholar
• HanYLiYWangSCilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled studyAm Heart J2009157473373919332203
   PubMed Web of Science ®Google Scholar
• AhnCMHongSJParkJHKimJSLimDSCilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-upHeart Vessels201126550251021153029
   PubMed Web of Science ®Google Scholar
• YounYJLeeJWAhnSGMulticenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery diseaseAm Heart J20141672241.e1248.e124439986
   PubMed Web of Science ®Google Scholar
• SaviPZachayusJLDelesque-TouchardNThe active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid raftsProc Natl Acad Sci U S A200610329110691107416835302
   PubMed Web of Science ®Google Scholar
• ChenJMengHXuLEfficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trialsJ Thromb Thrombolysis2015391233424869717
   PubMed Web of Science ®Google Scholar
• ItoCKusanoEFurukawaYModulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cellsAm J Physiol Cell Physiol20022836C1715C172112419709
   PubMed Web of Science ®Google Scholar
• HayashiSMorishitaRMatsushitaHCyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21Hypertension2000351 pt 223724310642304
   PubMed Web of Science ®Google Scholar
• InoueTUchidaTSakumaMCilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantationJ Am Coll Cardiol20044471408141415464320
   PubMed Web of Science ®Google Scholar